Cristina Bolzati
Overview
Explore the profile of Cristina Bolzati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
222
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salvarese N, Morellato N, Gobbi C, Gandin V, De Franco M, Marzano C, et al.
Dalton Trans
. 2024 Feb;
53(10):4526-4543.
PMID: 38348686
A library of homoleptic mononuclear Ga(III) complexes of the general formula [Ga(DTC)], where DTC is an alicyclic or a linear dithiocarbamate chelator, is reported. The complexes were prepared in high...
2.
Bolzati C, Gobbi C, Ferro-Flores G, Turato S, Ocampo-Garcia B, Carpanese D, et al.
Int J Mol Sci
. 2024 Jan;
25(1).
PMID: 38203663
Previously, we demonstrated that the Lu-labeled single-chain variable fragment of an anti-prostate-specific membrane antigen (PSMA) IgG D2B antibody (scFvD2B) showed higher prostate cancer (PCa) cell uptake and tumor radiation doses...
3.
Kleynhans J, Duatti A, Bolzati C
Molecules
. 2023 Feb;
28(3).
PMID: 36771153
The β emitter, rhenium-188 (Re), has long been recognized as an attractive candidate for targeted cancer radionuclide therapy (TRNT). This transition metal shares chemical similarities with its congener element technetium,...
4.
Brunello S, Salvarese N, Carpanese D, Gobbi C, Melendez-Alafort L, Bolzati C
Molecules
. 2022 May;
27(9).
PMID: 35565970
Recently, prostate-specific membrane antigen (PSMA) has gained momentum in tumor nuclear molecular imaging as an excellent target for both the diagnosis and therapy of prostate cancer. Since 2008, after years...
5.
Salvarese N, Carpanese D, Melendez-Alafort L, De Nardo L, Calderan A, Biondi B, et al.
Molecules
. 2022 Apr;
27(8).
PMID: 35458745
: The [Tc][Tc(N)(PNP)] system, where PNP is a bisphosphinoamine, is an interesting platform for the development of tumor '' agents. Here, we compared the reactivity and impact of three [Tc(N)(PNP)]...
6.
Bolzati C, Salvarese N, Spolaore B, Vittadini A, Forrer D, Brunello S, et al.
Mol Pharm
. 2022 Feb;
19(3):876-894.
PMID: 35188772
The incorporation of bioactive molecules into a water-soluble [Tc][Tc(N)(PNP)]-based mixed compound is described. The method, which exploits the chemical properties of the new [Tc][Tc(N)(PNP3OH)] synthon [PNP3OH = ,-bis(di-hydroxymethylenphosphinoethyl)methoxyethylamine], was successfully...
7.
Bolzati C, Spolaore B
Molecules
. 2021 Jul;
26(12).
PMID: 34201280
Site-specific conjugation of proteins is currently required to produce homogenous derivatives for medicine applications. Proteins derivatized at specific positions of the polypeptide chain can actually show higher stability, superior pharmacokinetics,...
8.
Melendez-Alafort L, Ferro-Flores G, Santos-Cuevas C, Ocampo-Garcia B, Turato S, Fracasso G, et al.
Med Phys
. 2021 May;
48(7):4064-4074.
PMID: 33966284
Purpose: Internal dosimetry has become a very important tool to evaluate the risks and benefits of new endoradiotherapeutic agents. Nowadays, some of the most successful targeted radionuclide therapy (TRT) agents...
9.
Bolzati C, Duatti A
Q J Nucl Med Mol Imaging
. 2020 Oct;
64(4):329-337.
PMID: 33026210
Along with other novel metallic radionuclides, copper-64 (Cu) is currently being investigated as an alternative option to the gallium-68 (Ga) and lutetium-177 (Lu) radiopharmaceuticals widely used for targeting somatostatin receptors,...
10.
Carpanese D, Ferro-Flores G, Ocampo-Garcia B, Santos-Cuevas C, Salvarese N, Figini M, et al.
Sci Rep
. 2020 Jun;
10(1):9313.
PMID: 32518372
The clinical translation of theranostic Lu-radiopharmaceuticals based on inhibitors of the prostate-specific membrane antigen (PSMA) has demonstrated positive clinical responses in patients with advanced prostate cancer (PCa). However, challenges still...